Investigational drugs for neuroendocrine tumours
Authors:
- 24 April 2009
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Investigational Drugs
- Vol. 18 (5) , 601-608
Abstract
Neuroendocrine tumours (NETs) are usually slow-growing neoplasms, which arise in the gastrointestinal tract, endocrine pancreas, lungs or thymus. The majority are malignant. The treatment of patients with metastatic disease consists of biotherapy with alpha-interferon and somatostatin analogues, various chemotherapy combinations or liver embolization. To review and discuss new treatments for patients with metastatic NETs. Review of the published literature during the last 5 years on treatment of patients with NETs. Several new drugs with various mechanisms of action including cytotoxic drugs, tyrosine kinase receptor inhibitors and antiangiogenic drugs as well as radiolabelled substances have been introduced during recent years. Many of these compounds have shown promising results in patients with NETs.Keywords
This publication has 52 references indexed in Scilit:
- Efficacy of RAD001 (Everolimus) and Octreotide LAR in Advanced Low- to Intermediate-Grade Neuroendocrine Tumors: Results of a Phase II StudyJournal of Clinical Oncology, 2008
- Barriers to Effective TRAIL-Targeted Therapy of MalignancyJournal of Clinical Oncology, 2007
- In ReplyJournal of Clinical Oncology, 2007
- P1-123: Response of atypical pulmonary carcinoid tumors to chemotherapy. A retrospective study of 37 patients.Journal of Thoracic Oncology, 2007
- Expression of Tyrosine Kinase Receptors in Malignant Midgut Carcinoid TumorsNeuroendocrinology, 2006
- A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomasBritish Journal of Cancer, 2006
- Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?Cancer Chemotherapy and Pharmacology, 2006
- Expression of Tyrosine Kinase Receptors in Lung CarcinoidsTumor Biology, 2006
- Epidermal growth factor receptor and activated epidermal growth factor receptor expression in gastrointestinal carcinoids and pancreatic endocrine carcinomasLaboratory Investigation, 2005
- A Phase II trial of gemcitabine for metastatic neuroendocrine tumorsCancer, 2004